FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056599112> ?p ?o ?g. }

• W2056599112 endingPage "S10" @default.
• W2056599112 startingPage "S7" @default.
• W2056599112 abstract "There are almost 100 different substances called uremic toxins. In this study, we analyze all findings concerning the new family of uremic compounds—nicotinamide end products: N-methyl-2-pyridone-5-carboxamide (Met2PY), N-methyl-4-pyridone-5-carboxamide, newly described 4-pyridone-3-carboxamide-1-β-d-ribonucleoside (4PYR) and 4-pyridone-3-carboxamide-1-β-d-ribonucleoside triphosphate (4PYTP). After few years of studies, we have found that these substances have higher plasma concentration in patients with chronic renal failure (CRF) in comparison with the healthy population. We noted a 40-fold increase in plasma 4PYR concentration in patients with CRF. This increment correlates significantly with the decline of kidney function measured as an increase of serum creatinine concentration and decrease of estimated glomerular filtration rate. Tested compounds are present and measurable in physiological fluids and tissues. We found higher saliva Met2PY concentration in patients with CRF in comparison with controls. Saliva Met2PY correlated negatively with estimated glomerular filtration rate and positively with serum creatinine concentration. One-third of studied group had higher concentration of Met2PY in the saliva than in plasma, and this segment of patients may be called as “good excretors.” In rats with experimental CRF, we found that both Met2PY and N-methyl-4-pyridone-5-carboxamide accumulated in selected tissues. We also demonstrated formation of 4PYTP in intact human erythrocytes during incubation with the precursor 4PYR. Incubation with 4PYR leads to lowering concentration of adenosine-5'-triphosphate. 4PYTP formation may be a way to remove 4PYR from the circulation and save adenosine-5'-triphosphate depletion. Summarizing, end products of the nicotinamide family are members of uremic toxins; however, exact pathophysiological role of these compounds in the development of uremic syndrome needs further studies. There are almost 100 different substances called uremic toxins. In this study, we analyze all findings concerning the new family of uremic compounds—nicotinamide end products: N-methyl-2-pyridone-5-carboxamide (Met2PY), N-methyl-4-pyridone-5-carboxamide, newly described 4-pyridone-3-carboxamide-1-β-d-ribonucleoside (4PYR) and 4-pyridone-3-carboxamide-1-β-d-ribonucleoside triphosphate (4PYTP). After few years of studies, we have found that these substances have higher plasma concentration in patients with chronic renal failure (CRF) in comparison with the healthy population. We noted a 40-fold increase in plasma 4PYR concentration in patients with CRF. This increment correlates significantly with the decline of kidney function measured as an increase of serum creatinine concentration and decrease of estimated glomerular filtration rate. Tested compounds are present and measurable in physiological fluids and tissues. We found higher saliva Met2PY concentration in patients with CRF in comparison with controls. Saliva Met2PY correlated negatively with estimated glomerular filtration rate and positively with serum creatinine concentration. One-third of studied group had higher concentration of Met2PY in the saliva than in plasma, and this segment of patients may be called as “good excretors.” In rats with experimental CRF, we found that both Met2PY and N-methyl-4-pyridone-5-carboxamide accumulated in selected tissues. We also demonstrated formation of 4PYTP in intact human erythrocytes during incubation with the precursor 4PYR. Incubation with 4PYR leads to lowering concentration of adenosine-5'-triphosphate. 4PYTP formation may be a way to remove 4PYR from the circulation and save adenosine-5'-triphosphate depletion. Summarizing, end products of the nicotinamide family are members of uremic toxins; however, exact pathophysiological role of these compounds in the development of uremic syndrome needs further studies." @default.
• W2056599112 created "2016-06-24" @default.
• W2056599112 creator A5021104852 @default.
• W2056599112 creator A5030670986 @default.
• W2056599112 creator A5032030602 @default.
• W2056599112 creator A5043134796 @default.
• W2056599112 date "2010-09-01" @default.
• W2056599112 modified "2023-10-16" @default.
• W2056599112 title "Distribution of Purine Nucleotides in Uremic Fluids and Tissues" @default.
• W2056599112 cites W1565445129 @default.
• W2056599112 cites W1964014783 @default.
• W2056599112 cites W1970655304 @default.
• W2056599112 cites W1998892139 @default.
• W2056599112 cites W2002389271 @default.
• W2056599112 cites W2047081483 @default.
• W2056599112 cites W2049360193 @default.
• W2056599112 cites W2050994180 @default.
• W2056599112 cites W2056301806 @default.
• W2056599112 cites W2121922233 @default.
• W2056599112 cites W2136796349 @default.
• W2056599112 cites W2144284973 @default.
• W2056599112 cites W2158242425 @default.
• W2056599112 doi "https://doi.org/10.1053/j.jrn.2010.05.003" @default.
• W2056599112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20797575" @default.
• W2056599112 hasPublicationYear "2010" @default.
• W2056599112 type Work @default.
• W2056599112 sameAs 2056599112 @default.
• W2056599112 citedByCount "10" @default.
• W2056599112 countsByYear W20565991122012 @default.
• W2056599112 countsByYear W20565991122015 @default.
• W2056599112 countsByYear W20565991122016 @default.
• W2056599112 countsByYear W20565991122017 @default.
• W2056599112 countsByYear W20565991122020 @default.
• W2056599112 countsByYear W20565991122021 @default.
• W2056599112 countsByYear W20565991122023 @default.
• W2056599112 crossrefType "journal-article" @default.
• W2056599112 hasAuthorship W2056599112A5021104852 @default.
• W2056599112 hasAuthorship W2056599112A5030670986 @default.
• W2056599112 hasAuthorship W2056599112A5032030602 @default.
• W2056599112 hasAuthorship W2056599112A5043134796 @default.
• W2056599112 hasConcept C104317684 @default.
• W2056599112 hasConcept C126322002 @default.
• W2056599112 hasConcept C134018914 @default.
• W2056599112 hasConcept C159641895 @default.
• W2056599112 hasConcept C181199279 @default.
• W2056599112 hasConcept C185592680 @default.
• W2056599112 hasConcept C25642318 @default.
• W2056599112 hasConcept C2776476023 @default.
• W2056599112 hasConcept C2776844798 @default.
• W2056599112 hasConcept C2776991684 @default.
• W2056599112 hasConcept C2778327999 @default.
• W2056599112 hasConcept C2779728014 @default.
• W2056599112 hasConcept C2780306776 @default.
• W2056599112 hasConcept C2908647359 @default.
• W2056599112 hasConcept C55493867 @default.
• W2056599112 hasConcept C67705224 @default.
• W2056599112 hasConcept C71924100 @default.
• W2056599112 hasConcept C99454951 @default.
• W2056599112 hasConceptScore W2056599112C104317684 @default.
• W2056599112 hasConceptScore W2056599112C126322002 @default.
• W2056599112 hasConceptScore W2056599112C134018914 @default.
• W2056599112 hasConceptScore W2056599112C159641895 @default.
• W2056599112 hasConceptScore W2056599112C181199279 @default.
• W2056599112 hasConceptScore W2056599112C185592680 @default.
• W2056599112 hasConceptScore W2056599112C25642318 @default.
• W2056599112 hasConceptScore W2056599112C2776476023 @default.
• W2056599112 hasConceptScore W2056599112C2776844798 @default.
• W2056599112 hasConceptScore W2056599112C2776991684 @default.
• W2056599112 hasConceptScore W2056599112C2778327999 @default.
• W2056599112 hasConceptScore W2056599112C2779728014 @default.
• W2056599112 hasConceptScore W2056599112C2780306776 @default.
• W2056599112 hasConceptScore W2056599112C2908647359 @default.
• W2056599112 hasConceptScore W2056599112C55493867 @default.
• W2056599112 hasConceptScore W2056599112C67705224 @default.
• W2056599112 hasConceptScore W2056599112C71924100 @default.
• W2056599112 hasConceptScore W2056599112C99454951 @default.
• W2056599112 hasIssue "5" @default.
• W2056599112 hasLocation W20565991121 @default.
• W2056599112 hasLocation W20565991122 @default.
• W2056599112 hasOpenAccess W2056599112 @default.
• W2056599112 hasPrimaryLocation W20565991121 @default.
• W2056599112 hasRelatedWork W1965943749 @default.
• W2056599112 hasRelatedWork W1978639835 @default.
• W2056599112 hasRelatedWork W2026105695 @default.
• W2056599112 hasRelatedWork W2031470785 @default.
• W2056599112 hasRelatedWork W2056270585 @default.
• W2056599112 hasRelatedWork W2074641809 @default.
• W2056599112 hasRelatedWork W2130981205 @default.
• W2056599112 hasRelatedWork W2208307236 @default.
• W2056599112 hasRelatedWork W2320914227 @default.
• W2056599112 hasRelatedWork W2748952813 @default.
• W2056599112 hasVolume "20" @default.
• W2056599112 isParatext "false" @default.
• W2056599112 isRetracted "false" @default.
• W2056599112 magId "2056599112" @default.
• W2056599112 workType "article" @default.